Haemophilia Treatment Market is Expected to Reach $16.16 bn by 2026
The Haemophilia Treatment Market was valued at US$10.84 billion in the year 2018 and is estimated to reach US$16.16 billion by 2026, at a CAGR of 5.12%.
Haemophilia is an X-linked recessive bleeding disorder characterized by a mutation in the X-chromosome. The disorder is more prevalent in the male population as the mutation occurs in the only X-chromosome present while the occurrence in the female population it is a rarity as both the X-chromosomes should be affected. However, the female population serves as a carrier. Haemophilia leads to profuse bleeding following an injury or surgery due to a lack of clotting factors. This is attributed to low levels of clotting factors such as factor XIII and factor IX. The adverse consequence of haemophilia is the mortality of the affected individual.
Early screening of neonates for a mutation in the X chromosome and increasing research and development activities are expected to find a definitive treatment for haemophilia and are likely to contribute to the growing market throughout the forecast period. Further, the increase in the individuals suffering from haemophilia is also on the rise and is expected to contribute to the sales of haemophilia treatments. However, the reimbursement policies across geographies and an increase in the cost of treatment options are likely to affect market growth. Additionally, there is a lack of awareness among the individuals among low-income and middle-income countries which is also expected to affect the market growth. Furthermore, there are several challenges such as treatment length, lack of expertise to treat the complications, diagnosis of haemophilia (due to its complexity) and development of inhibitors within the individuals can affect the treatment procedures. However, recent government initiatives to support the development of therapeutics for treating haemophilia and creating awareness are likely to contribute to the growth.
In the year 2018, North American region contributed more than 40% to the market growth and is expected to contribute further due to increasing number of hemophilic patients present in the region, increase in the inclination to prescribe prophylaxis treatment for patients to curb the diseases, prevalence of major market players in the region and also presence of major organization, FDA, which is responsible for approving drugs. The European region contributed more than 30% to the market growth followed by APAC and LAMEA regions.
According to the Haemophilia Foundation, till 2018, the total number of individuals with haemophilia was found to be 196706 with 158225 hemophilia A (factor XIII) and 31247 hemophilia B (factor IX) cases. This has contributed to the global per capita usage of factor VIII to 2.61 IU and that of factor IX to 0.40 IU. Incidentally, the pharmaceutical industry focuses more on treating type A with advate and recombinate being the popular drugs for treatment. However, there is an increase in Haemophilia B patient in recent times and is expected to contribute to the Type B market.
There were 600 clinical trials on Haemophilia reported in clinicaltrials.gov by the end of November 2019. Companies such as Novo Nordisk, Biogen, Chugai Pharmaceuticals, Bayer, Pfizer, Takeda, Baxalta, CSL Behring, Octapharma, BioMarin Pharma, etc. are the key players in the market. The major drugs used for treating haemophilia are peptide-based with Hemlibra from Chugai Pharma being a monoclonal antibody. BeneFIX from Pfizer is a peptide-based drug used for treating hemophilia B. Gene-based therapies are the next line of technological development expected to address the rising concerns in haemophilia treatment wherein gene therapies from Pfizer and Bayer are already in clinical trials. Further, clinical phase studies are underway for Green Cross Corporation and Sinocelltech.
The Haemophilia Treatment Market Report is segmented based on Type (Haemophilia A, B & C), By Therapy (On-demand & Prophylaxis), By Treatment (Replacement Therapy, ITI Therapy, and Gene Therapy) and By Region (North America, Europe, APAC and LAMEA).
The Haemophilia Treatment Market Analytics report from Optima Insights is a part of the First Series on Rare Disorders consisting of a detailed analysis of the epidemiology, products, pipeline drugs, key drivers & restraints, challenges, reimbursement policies on the inherited metabolic disorders that require more attention. Further, every part of the rare metabolic disorder series will cover 10 disorders categorized based on country prevalence and occurrence.
Request for Sample Pages @ https://www.optimainsights.org/sample-request/31-global-hemophilia-treatment-market-to-2024
- Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
- Provides a Comparative Analysis of Key Marketed and Pipeline Products.
- Provides Key Information on Players involved.
- Provides a Complete Overview of Market Segments and the Regional Outlook.
- Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
- History of the Haemophilia Treatment Market, 2015 to 2017
- Forecast of the Haemophilia Treatment Market Growth till the year 2026
- The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Haemophilia Treatment Market
- Analysis of potential growth segments which will drive the market
- Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
- Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/31-global-hemophilia-treatment-market-to-2024
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)